Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
47
IONS Quote, Financials, Valuation and Earnings
Last price:
$74.80
Seasonality move
:
5.95%
Day range:
$73.35 - $75.13
52-week range:
$23.95 - $86.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.08x
P/B ratio:
25.15x
Volume:
1.8M
Avg. volume:
2.5M
1-year change:
160.5%
Market cap:
$12.3B
Revenue:
$943.7M
EPS (TTM):
-$2.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$198.2M | -$0.78 | 51.16% | -16.46% | $96.81 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
BIIB
Biogen, Inc.
|
$2.2B | $3.03 | -4.12% | 85.49% | $207.33 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$952.5M | $1.10 | 3.04% | 4.71% | $88.87 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$147.3M | $0.64 | 4.12% | 42.15% | $34.00 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$148.8M | -$0.39 | 33.34% | -31.02% | $125.36 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$74.79 | $96.81 | $12.3B | -- | $0.00 | 0% | 13.08x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
BIIB
Biogen, Inc.
|
$177.34 | $207.33 | $25.1B | 19.43x | $0.00 | 0% | 2.63x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$24.69 | $34.00 | $3B | 14.57x | $0.00 | 0% | 5.30x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$94.17 | $125.36 | $5.7B | -- | $0.00 | 0% | 9.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
84.24% | 2.976 | 20.24% | 3.51x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BIIB
Biogen, Inc.
|
26.72% | 0.729 | 25.77% | 1.70x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.29% | -0.898 | 0.1% | 5.68x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
50.38% | 1.116 | 7.79% | 2.46x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$191.1M | -$215M | -14.26% | -67.97% | -105.91% | -$160.4M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BIIB
Biogen, Inc.
|
$1.5B | $372.1M | 5.34% | 7.36% | 17.06% | $401.7M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$117.1M | $61.8M | 25.11% | 25.2% | 40.53% | $44.9M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$120.6M | -$4.6M | -4.01% | -8.84% | -3.07% | $5.5M |
Ionis Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns IONS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of 16.99%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About IONS or ALNY?
Ionis Pharmaceuticals, Inc. has a consensus price target of $96.81, signalling upside risk potential of 29.44%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is IONS or ALNY More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.399, which suggesting that the stock is 60.146% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock IONS or ALNY?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or ALNY?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.08x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns IONS or BIIB?
Biogen, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -2.24%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Biogen, Inc.'s return on equity of 7.36%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B BIIBBiogen, Inc.68.12% -$0.33 $24.9B -
What do Analysts Say About IONS or BIIB?
Ionis Pharmaceuticals, Inc. has a consensus price target of $96.81, signalling upside risk potential of 29.44%. On the other hand Biogen, Inc. has an analysts' consensus of $207.33 which suggests that it could grow by 16.74%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 BIIBBiogen, Inc.13 19 1 -
Is IONS or BIIB More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.399, which suggesting that the stock is 60.146% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.797%.
-
Which is a Better Dividend Stock IONS or BIIB?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or BIIB?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Biogen, Inc.'s net income of -$48.9M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 19.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.08x versus 2.63x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M BIIBBiogen, Inc.2.63x 19.43x $2.2B -$48.9M
-
Which has Higher Returns IONS or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -5.2%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About IONS or BMRN?
Ionis Pharmaceuticals, Inc. has a consensus price target of $96.81, signalling upside risk potential of 29.44%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is IONS or BMRN More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.399, which suggesting that the stock is 60.146% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock IONS or BMRN?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or BMRN?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.08x versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns IONS or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of 34.53%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B CPRXCatalyst Pharmaceuticals, Inc.76.71% $0.41 $957.1M -
What do Analysts Say About IONS or CPRX?
Ionis Pharmaceuticals, Inc. has a consensus price target of $96.81, signalling upside risk potential of 29.44%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 37.71%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is IONS or CPRX More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.399, which suggesting that the stock is 60.146% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.264%.
-
Which is a Better Dividend Stock IONS or CPRX?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or CPRX?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.08x versus 5.30x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M CPRXCatalyst Pharmaceuticals, Inc.5.30x 14.57x $152.6M $52.7M
-
Which has Higher Returns IONS or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -3.85%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Mirum Pharmaceuticals, Inc.'s return on equity of -8.84%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B MIRMMirum Pharmaceuticals, Inc.80.97% -$0.11 $634.1M -
What do Analysts Say About IONS or MIRM?
Ionis Pharmaceuticals, Inc. has a consensus price target of $96.81, signalling upside risk potential of 29.44%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $125.36 which suggests that it could grow by 33.13%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 MIRMMirum Pharmaceuticals, Inc.8 0 0 -
Is IONS or MIRM More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.399, which suggesting that the stock is 60.146% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.585%.
-
Which is a Better Dividend Stock IONS or MIRM?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or MIRM?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are larger than Mirum Pharmaceuticals, Inc. quarterly revenues of $148.9M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Mirum Pharmaceuticals, Inc.'s net income of -$5.7M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.08x versus 9.31x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M MIRMMirum Pharmaceuticals, Inc.9.31x -- $148.9M -$5.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
